Drug Profile
Varisacumab - Affitech Research/International Biotech Center Generium/OncXerna Therapeutics
Alternative Names: Anti-VEGF antibody AT001/r84; Apagin; AT-001 - IBCG; AT001/r84; Bevacizumab biosimilar - International Biotech Center Generium; Fully humanised monoclonal antibody to VEGF; GNR-011; R-84Latest Information Update: 02 Apr 2024
Price :
$50
*
At a glance
- Originator Peregrine Pharmaceuticals; University of Texas Southwestern Medical Center
- Developer Affitech Research AS
- Class Antibodies; Antineoplastics; Eye disorder therapies; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Angiogenesis inhibitors; Vascular endothelial growth factor A inhibitors; Vascular endothelial growth factor receptor-2 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Breast cancer; Colorectal cancer; Eye disorders; Glioblastoma; Non-small cell lung cancer
Most Recent Events
- 27 Sep 2021 Discontinued - Phase-II/III for Breast cancer in Russia (IV)
- 27 Sep 2021 Discontinued - Phase-II/III for Colorectal cancer in Russia (IV)
- 27 Sep 2021 Discontinued - Phase-II/III for Eye disorders in Russia (IV)